BioCentury | Sep 16, 2020
Product Development

Frequency’s long-term hearing loss readout points to hair cell regeneration

Frequency’s data showing its hearing loss therapy can sustain improvements in word recognition for over a year back the product’s potential to regenerate lost hair cells, Chief Development Officer Carl...
BioCentury | Sep 11, 2020
Product Development

Pfizer’s MacKenzie: Other diseases deserve the same acceleration as COVID-19: a BioCentury audio interview

Pfizer’s Rod MacKenzie says the collaborations and accelerated timelines taking place during COVID-19 are causing introspection in pharmas for how they operate, and for how they can push for regulators...
BioCentury | Sep 11, 2020
Product Development

Hamburg on how COVID-19 collaboration models could propel drug development for public health priorities: a BioCentury audio interview

The extraordinary collaboration and commitment on the part of biopharma companies and governments that COVID-19 has inspired should serve as models for addressing unmet medical needs after the crisis has passed, Margaret Hamburg, who served...
BioCentury | Sep 11, 2020
Product Development

COVID-19 should spur massive investment in science and technology, Regeneron’s Yancopoulos says: a BioCentury audio interview

In addition to preparing for future pandemics, the U.S. should increase its investments in science and technology by orders of magnitude to head off crippling onslaughts of disease, Regeneron’s George Yancopoulos told BioCentury. In a...
BioCentury | Sep 10, 2020
Product Development

Qiming’s Leung: COVID-19 response displays the deep networks of China’s biotech ecosystem: a BioCentury audio interview

The picture Nisa Leung, managing director of Qiming Venture Partners, paints of the response among Chinese biotechs to COVID-19 is one that underscores how the local ecosystem has matured from a “budding...
BioCentury | Sep 10, 2020
Product Development

Oxford’s Landray wants RECOVERY-type trials to go well beyond COVID-19: a BioCentury audio interview

Oxford University’s Martin Landray, one of the two initiators of the U.K.’s RECOVERY trial, said while the first consideration in designing the adaptive platform trial was to find a cure for COVID-19 as...
BioCentury | Sep 10, 2020
Product Development

Takeda’s Weber expects expansion of precompetitive space, new alliance formats coming out of COVID-19: a BioCentury audio interview

Takeda President and CEO Christophe Weber says COVID-19 could permanently change the way drugs are developed by leading companies to expand the precompetitive space and enter into new kinds of alliances....
BioCentury | Sep 9, 2020
Product Development

BMS’s Hirawat says health equity should be on all biopharmas’ agendas: a BioCentury audio interview

BMS CMO Samit Hirawat believes that all biopharmas can, and should, contribute to eliminating racial, ethnic and socioeconomic disparities in health outcomes. The responsibility, he says, extends from working with minority communities directly to holding...
BioCentury | Sep 9, 2020
Product Development

Roche’s Anderson wants industry to keep its foot on the gas for infectious disease, post-pandemic: a BioCentury audio interview

There will be no turning back to business as usual for drug developers and regulators after COVID-19, according to Bill Anderson, CEO of Roche Pharmaceuticals. But while he’s optimistic about speeding up timelines and changing...
BioCentury | Sep 7, 2020
Product Development

Bingham on U.K.’s flexible surge capacity in COVID-19 as foundation for future: a BioCentury audio interview

Kate Bingham expects that manufacturing infrastructure being created in the U.K. will make the country far better prepared for future outbreaks, and that closer working relationships between drug developers and regulators, as well as among...
Items per page:
1 - 10 of 1367